CHI-921

Investigation of the Efficacy and Safety of CHI-921 in Insomnia.

Ensayo de Canopy Growth Corp en Insomnia (del registro, en inglés).

Fase: Fase 2
Estado: Interrumpido
Participantes: 21
Centros: 1
Fin del objetivo primario: jun 2020

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en mar 2019.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «COVID-19».

Qué mide

Change from baseline of PSG latency to persistent sleep (after 3 weeks per treatment dose with CHI-921 compared to placebo) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroInsomnia is a disorder where people are having trouble sleeping and can include difficulty falling asleep, staying asleep and waking up too early, as well as having unrefreshing sleep. CHI-921 is a cannabis extract in sunflower oil produced as a treatment for insomnia. This trial is designed to evaluate the efficacy and safety of CHI-921 on people with insomnia.

Más ensayos de CGC

Ensayo	Fase	Estado	Lectura de resultados
Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain	no aplica	Sin noticias del promotor	jul 2023 (prevista, ya pasada: sin actualizar en el registro)
A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality	Fase 1/2	Completado	dic 2022 (real)
CBD	Fase 1	Interrumpido	sep 2022 (real)
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants	Fase 1	Completado	may 2022 (real)
Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity	Fase 2	Completado	feb 2022 (real)
Cannabidiol	Fase 2	Completado	sep 2021 (real)

Todos los de CGC, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03984604), actualizada en sep 2020.